Regulatory T cells engineered with TCR signaling–responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter
Authors:
- 11 November 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (569)
Abstract
Adoptive cell transfer of ex vivo expanded regulatory T cells (Tregs) has shown immense potential in animal models of auto- and alloimmunity. However, the effective translation of such Treg therapies to the clinic has been slow. Because Treg homeostasis is known to require continuous T cell receptor (TCR) ligation and exogenous interleukin-2 (IL-2), some investigators have explored the use of low-dose IL-2 injections to increase endogenous Treg responses. Systemic IL-2 immunotherapy, however, can also lead to the activation of cytotoxic T lymphocytes and natural killer cells, causing adverse therapeutic outcomes. Here, we describe a drug delivery platform, which can be engineered to autostimulate Tregs with IL-2 in response to TCR-dependent activation, and thus activate these cells in sites of antigen encounter. To this end, protein nanogels (NGs) were synthesized with cleavable bis(N-hydroxysuccinimide) cross-linkers and IL-2/Fc fusion (IL-2) proteins to form particles that release IL-2 under reducing conditions, as found at the surface of T cells receiving stimulation through the TCR. Tregs surface-conjugated with IL-2 NGs were found to have preferential, allograft-protective effects relative to unmodified Tregs or Tregs stimulated with systemic IL-2. We demonstrate that murine and human NG–modified Tregs carrying an IL-2 cargo perform better than conventional Tregs in suppressing alloimmunity in murine and humanized mouse allotransplantation models. In all, the technology presented in this study has the potential to improve Treg transfer therapy by enabling the regulated spatiotemporal provision of IL-2 to antigen-primed Tregs.Keywords
Funding Information
- National Institutes of Health (AI134842)
- National Institutes of Health (T32 DK007527)
- American Diabetes Association (1-17-IBS-206)
- American Heart Association (13FTF17000018)
- Qatar Foundation (NPRP8-1744-3-357X)
This publication has 69 references indexed in Scilit:
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasisSeminars in Immunology, 2012
- Rendering Protein-Based Particles Transiently Insoluble for Therapeutic ApplicationsJournal of the American Chemical Society, 2012
- Response to self antigen imprints regulatory memory in tissuesNature, 2011
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivoNature Immunology, 2009
- Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the MorningImmunity, 2009
- Heterogeneity of natural Foxp3 + T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticityProceedings of the National Academy of Sciences, 2009
- Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytesNature Medicine, 2007
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006